During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims about compounded GLP-1 productsclaims the agency views as violating the Federal Food, Drug, and Cosmetic Acts (FDCA) misbranding provisions, including Sections 502(a) and 502(n)
Furthermore, antihypertensive drugs that do not block the SNS may exhibit an increasing BP effect of DPP-4 inhibitors by lowering basal vascular tone (86)
If GLP-1 coverage is important to you, do not assume your current access carries over
What makes one LifeWave patch different than another
For peptides that do not dissolve well in neutral water, acetic acid water may be used as a first step solvent to improve solubility, especially for hydrophobic or basic peptides
D.SteinA